Drug Profile


Alternative Names: JNJ-3872; JNJ-63623872; JNJ-872; VX 787

Latest Information Update: 07 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer Janssen Pharmaceuticals; Vertex Pharmaceuticals
  • Class Antivirals; Pyridines; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Viral protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza A virus infections

Most Recent Events

  • 23 Jun 2017 Efficacy and adverse event data from the phase IIb Topaz trial in Influenza-A virus infections released by Janssen Pharmaceuticals
  • 14 Jun 2017 Janssen Pharmaeuticals plans phase III trials for Influenza A in the second half of 2017
  • 17 May 2017 Johnson & Johnson Pharmaceuticals announces intention to submit regulatory filings for pimodivir in Influenza-A virus infections in between 2017 and 2021
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top